Late-Onset Immune-Related Adverse Events After Immune Checkpoint Inhibitor Therapy
The findings of this retrospective observational cohort study suggest that late irAEs are possible, with a subset of patients presenting years after the start of ICI therapy. Clinicians must remain vigilant for irAEs regardless of elapsed time from ICI therapy, especially as patients live longer and ICIs become more widely used. Future investigations are needed to better understand the risk factors for late-onset irAEs and the distinct immunologic pathways that underlie such events.
Authors
- Ayo Samuel Falade (ORCID: https://orcid.org/0000-0001-9201-6998)
- Mike Wang (ORCID: https://orcid.org/0000-0001-6487-5912)
- Gabriel E. Molina (ORCID: https://orcid.org/0000-0002-2608-6629)
- Nishi Shah (ORCID: https://orcid.org/0000-0002-8679-511X)
- Kerry L. Reynolds (ORCID: https://orcid.org/0000-0002-7793-654X)
- Ted V. Jacoby (ORCID: https://orcid.org/0000-0003-0983-5349)
- Leyre Zubiri
- Kelley Grealish
- Nora Hathaway (ORCID: https://orcid.org/0009-0009-2428-9367)
- Sienna Durbin (ORCID: https://orcid.org/0000-0002-6096-7294)
- Meghan J. Mooradian (ORCID: https://orcid.org/0000-0002-8289-8015)
- Jaclyn LoPiccolo (ORCID: https://orcid.org/0000-0003-0043-0206)
- Tristan Lim (ORCID: https://orcid.org/0000-0002-3798-5400)
- Chia‐Yun Wu
- Katherine Perlman
Institutions
- Mayo Clinic (US)
- Harvard University (US)
- Salem Hospital (US)
- University of Chicago (US)
- Massachusetts General Hospital (US)
- Far Eastern Memorial Hospital (TW)
- Dana-Farber Cancer Institute (US)
Publication Details
- Journal
- JAMA Network Open
- Published
- 2025-03-27
- DOI
- https://doi.org/10.1001/jamanetworkopen.2025.2668
- Citations
- 30
- Primary Topic
- Cancer Immunotherapy and Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 31.36